MORD Stock Overview Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for MorphoSys Historical stock prices Current Share Price €67.63 52 Week High €67.70 52 Week Low €14.79 Beta 0.67 1 Month Change 0% 3 Month Change 1.12% 1 Year Change 143.26% 3 Year Change 47.54% 5 Year Change -38.02% Change since IPO 234.28%
Recent News & Updates MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market Aug 05
MorphoSys AG, Annual General Meeting, Aug 27, 2024 Jul 22 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market Jul 13
MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024 Jul 04
MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance) Jun 26 MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index See more updates MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market Aug 05
MorphoSys AG, Annual General Meeting, Aug 27, 2024 Jul 22 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market Jul 13
MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024 Jul 04
MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance) Jun 26 MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index MorphoSys AG Announces Board Changes Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys May 18
New major risk - Negative shareholders equity May 06
First quarter 2024 earnings released: €8.27 loss per share (vs €1.30 loss in 1Q 2023) May 02
Investor sentiment improves as stock rises 69% Feb 07
Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion. Feb 07 Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.
MorphoSys AG Provides Sales Guidance for the Financial Year 2024 Jan 31
New minor risk - Shareholder dilution Jan 09
Investor sentiment improves as stock rises 70% Dec 20 MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024 MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million. Dec 15
MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024
MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study Dec 11
MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib Nov 21
New major risk - Financial position Nov 19
Third quarter 2023 earnings released: €3.50 loss per share (vs €3.60 loss in 3Q 2022) Nov 18
Investor sentiment improves as stock rises 27% Nov 09
MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting Nov 03
Morphosys AG Provides Earnings Guidance for the Year 2023 Oct 26
Investor sentiment deteriorates as stock falls 15% Oct 03 Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR). Sep 17
Investor sentiment improves as stock rises 16% Sep 15
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer Sep 14
New major risk - Revenue and earnings growth Aug 11
Second quarter 2023 earnings released: €2.16 loss per share (vs €6.88 loss in 2Q 2022) Aug 11
MorphoSys AG Provides Earnings Guidance for the Year 2023 Aug 10
First quarter 2023 earnings released: €1.30 loss per share (vs €3.59 loss in 1Q 2022) May 06
Morphosys Ag Provides Sales Guidance for the Financial Year 2023 May 06
Full year 2022 earnings released: €4.42 loss per share (vs €15.40 loss in FY 2021) Mar 17
MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 Jan 09 MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022 MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023
Third quarter 2022 earnings released: €3.60 loss per share (vs €3.30 loss in 3Q 2021) Nov 19
MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Oct 28
Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022 Oct 22
MorphoSys AG Announces Executive Changes Sep 01
Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022 Jul 27
MorphoSys AG Confirms Financial Guidance for the Year 2022 Jun 24 MorphoSys AG Announces Supervisory Board Changes May 19
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 19
MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis Dec 13
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 12
Third quarter 2021 earnings released: €3.30 loss per share (vs €2.00 loss in 3Q 2020) Nov 11
Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Aug 26
Second quarter 2021 earnings released: EPS €0.64 (vs €1.62 loss in 2Q 2020) Jul 30
MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST). Jul 16
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jun 26
MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting May 21
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma May 12
First quarter 2021 earnings released: €1.27 loss per share (vs €6.12 profit in 1Q 2020) May 10
MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021 May 07
Full year 2020 earnings released: EPS €3.01 (vs €3.26 loss in FY 2019) Mar 18
New 90-day low: €88.08 Feb 20
New 90-day high: €101 Jan 27 Shareholder Returns MORD GB Biotechs GB Market 7D 0% -1.9% -0.6% 1Y 143.3% -25.0% 2.7%
See full shareholder returns
Return vs Industry: MORD exceeded the UK Biotechs industry which returned -26.2% over the past year.
Return vs Market: MORD exceeded the UK Market which returned 6.4% over the past year.
Price Volatility Is MORD's price volatile compared to industry and market? MORD volatility MORD Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: MORD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MORD's volatility change over the past year.
About the Company MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.
Show more MorphoSys AG Fundamentals Summary How do MorphoSys's earnings and revenue compare to its market cap? MORD fundamental statistics Market cap €2.53b Earnings (TTM ) -€468.57m Revenue (TTM ) €241.47m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MORD income statement (TTM ) Revenue €241.47m Cost of Revenue €60.14m Gross Profit €181.33m Other Expenses €649.90m Earnings -€468.57m
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
Earnings per share (EPS) -12.44 Gross Margin 75.09% Net Profit Margin -194.05% Debt/Equity Ratio -658.0%
How did MORD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/08/04 06:59 End of Day Share Price 2024/06/24 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MorphoSys AG is covered by 35 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Olav Zilian Baader Helvea Equity Research Brian Balchin Barclays Rosie Turner Barclays
Show 32 more analysts 
